Cargando…

S40. COMBINING PHARMACOTHERAPY OF BI 425809 WITH COMPUTERISED COGNITIVE TRAINING IN PATIENTS WITH SCHIZOPHRENIA: INITIAL EXPERIENCE OF A LARGE-SCALE MULTICENTRE RANDOMISED CLINICAL TRIAL

BACKGROUND: There are currently no approved medications for cognition in patients with schizophrenia. BI 425809, a glycine transporter 1 inhibitor, increases glycine in the synaptic cleft and may improve glutamatergic neurotransmission, synaptic neuroplasticity, and cognition. Pharmacotherapies targ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hake, Sanjay, Huang, Songqiao, McDonald, Sean, Pollentier, Stephane, Podhorna, Jana
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Poster Session I
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7233981/ http://dx.doi.org/10.1093/schbul/sbaa031.106

Ejemplares similares

Evaluation of the Efficacy of BI 425809 Pharmacotherapy in Patients with Schizophrenia Receiving Computerized Cognitive Training: Methodology for a Double-blind, Randomized, Parallel-group Trial
por: Harvey, Philip D., et al.
Publicado: (2020)

Development of the novel GlyT1 inhibitor, iclepertin (BI 425809), for the treatment of cognitive impairment associated with schizophrenia
por: Rosenbrock, Holger, et al.
Publicado: (2023)

The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]-BI 425809 in Healthy Males
por: Burkard, Ute, et al.
Publicado: (2021)

Correction to: The Absolute Bioavailability, Absorption, Distribution, Metabolism, and Excretion of BI 425809 Administered as an Oral Dose or an Oral Dose with an Intravenous Microtracer Dose of [(14)C]‑BI 425809 in Healthy Males
por: Burkard, Ute, et al.
Publicado: (2022)

Efficacy and safety of iclepertin (BI 425809) in patients with schizophrenia: CONNEX, a Phase III randomised controlled trial programme
por: Falkai, P., et al.
Publicado: (2023)

S32. ARE SELECTIVE ESTROGEN RECEPTOR BETA AGONISTS POTENTIAL THERAPEUTICS FOR SCHIZOPHRENIA?
por: Breier, Alan, et al.
Publicado: (2020)

S83. MORTALITY, REVASCULARIZATION AND CARDIOPROTECTIVE PHARMACOTHERAPY AFTER ACUTE CORONARY SYNDROME IN PATIENTS WITH PSYCHOTIC DISORDERS: A POPULATION-BASED COHORT STUDY
por: Chung Chang, Wing, et al.
Publicado: (2020)

S170. PROGRESSIVE SUBCORTICAL VOLUME LOSS IN TREATMENT-RESISTANT SCHIZOPHRENIA PATIENTS AFTER COMMENCING CLOZAPINE TREATMENT
por: Tronchin, Giulia, et al.
Publicado: (2020)

S176. A PRELIMINARY INVESTIGATION OF COMT GENE INVOLVEMENT IN COGNITIVE FLEXIBILITY AND ATTENTION IN SCHIZOPHRENIA SPECTRUM DISORDERS
por: Morris, Kim, et al.
Publicado: (2020)

Quantitative electroencephalography parameters as neurophysiological biomarkers of schizophrenia-related deficits: A Phase II substudy of patients treated with iclepertin (BI 425809)
por: Schultheis, Christian, et al.
Publicado: (2022)

S156. PUBLIC ATTENTION TO CRIME OF SCHIZOPHRENIA AND ITS CORRELATION WITH USE OF MENTAL HEALTH SERVICES IN PATIENTS WITH SCHIZOPHRENIA
por: Park, Hyunwoo, et al.
Publicado: (2020)

S91. OPIOID USE AND SCHIZOPHRENIA: AN UPDATE
Publicado: (2020)

Evaluation of Pharmacokinetics and Pharmacodynamics of BI 425809, a Novel GlyT1 Inhibitor: Translational Studies
por: Rosenbrock, Holger, et al.
Publicado: (2018)

S198. SELF-DISTURBANCES AND THEIR NEURAL SIGNATURES IN SCHIZOPHRENIA
por: Zaytseva, Yulia, et al.
Publicado: (2020)

S155. DIETARY PATTERNS AND OBESITY IN INDIVIDUALS WITH SCHIZOPHRENIA
por: Amirah Abdul Rashid, Nur, et al.
Publicado: (2020)

S142. NOVEL CONCEPTS OF SOCIAL IMPAIRMENTS IN SCHIZOPHRENIA
por: Bitsch, Florian, et al.
Publicado: (2020)

S158. URBANICITY INDEX AND CORTICAL GYRIFICATION IN SCHIZOPHRENIA
por: Korann, Vittal, et al.
Publicado: (2020)

S62. COGNITIVE DEFICITS IN TREATMENT RESISTANT SCHIZOPHRENIA
por: Millgate, Edward, et al.
Publicado: (2020)

S237. MODERATORS AND RELATIONSHIPS OF COGNITION AND SUBJECTIVE QUALITY OF LIFE IN SCHIZOPHRENIA
por: Tan, Eric, et al.
Publicado: (2020)

S223. DETERMINANTS OF SUSTAINED UNEMPLOYMENT IN FORMERLY EMPLOYED SCHIZOPHRENIA PATIENTS
por: Fundora-Trujillo, Cynthia, et al.
Publicado: (2020)

S233. INTERNALIZED STIGMA IN PATIENTS WITH SCHIZOPHRENIA - A TRANSCULTURAL STUDY
Publicado: (2020)

S66. USING UNITIZATION TO CIRCUMVENT RELATIONAL MEMORY DEFICITS IN SCHIZOPHRENIA
por: de Sousa, Ana Elisa Farias, et al.
Publicado: (2020)

S194. CLOZAPINE AND ELECTROCONVULSIVE THERAPY AUGMENTATION IN ADOLESCENTS WITH TREATMENT-RESISTANT SCHIZOPHRENIA
por: Jeong Park, Kee, et al.
Publicado: (2020)

S149. CHANGES IN FRONTO-PARIETAL CONNECTIVITY IN SCHIZOPHRENIA: TMS AND FNIRS STUDY
por: Ćurčić-Blake, Branislava, et al.
Publicado: (2020)

S168. THE ASSOCIATION BETWEEN MMP-9 AND CHOROID PLEXUS VOLUME IN SCHIZOPHRENIA
por: Seethaler, Magdalena, et al.
Publicado: (2020)

S97. IS EARLY DEBUT OF SUBSTANCE USE ASSOCIATED WITH VIOLENT OFFENDING IN SCHIZOPHRENIA?
por: Breivik Storvestre, Guttorm, et al.
Publicado: (2020)

S116. PRAGMATIC COMPREHENSION IN SCHIZOPHRENIA: A SYSTEMATIC REVIEW AND META-ANALYSIS
por: Parola, Alberto, et al.
Publicado: (2020)

S190. WHEN WORDS AREN’T ENOUGH: DANCE/MOVEMENT THERAPY AND SCHIZOPHRENIA
por: Biondo, Jacelyn, et al.
Publicado: (2020)

S191. A SCOPING REVIEW AND PHENOMENOLOGICAL EVALUATION OF METACOGNITIVE TRAINING FOR SCHIZOPHRENIA
por: Brar, Pavan, et al.
Publicado: (2020)

S78. TIME PREDICTION AND SENSE OF SELF: LACK OF FLEXIBILITY IN PATIENTS WITH SCHIZOPHRENIA
por: Giersch, Anne, et al.
Publicado: (2020)

S16. INDEPENDENT SUPPORT FOR CORTICOPALLIDAL CONTRIBUTIONS TO SCHIZOPHRENIA-RELATED FUNCTIONAL IMPAIRMENT
Publicado: (2020)

S50. COGNITION AND EMOTION REGULATION IN SCHIZOPHRENIA PATIENTS WITH A HISTORY OF AGGRESSION
por: Ahmed, Anthony, et al.
Publicado: (2020)

S187. EXPLORING NEURODEVELOPMENTAL AND FAMILIAL ORIGINS OF NEUROLOGICAL SOFT SIGNS IN SCHIZOPHRENIA
por: Cooper, Rebecca, et al.
Publicado: (2020)

S184. IN SILICO PREDICTION OF T-CELL-MEDIATED MOLECULAR MIMICRY IN TOXOPLASMOSIS AND SCHIZOPHRENIA
por: Thylur, David, et al.
Publicado: (2020)

S49. THE RELATION BETWEEN PROCESSING SPEED AND USAGE OF MOBILE APPLICATIONS IN PATIENTS WITH SCHIZOPHRENIA
por: Hoşgelen, Emine Ilgın, et al.
Publicado: (2020)

S17. GLOBAL DNA METHYLATION IN CURRENT AND EMERGENT SUICIDAL IDEATION: ANALYSIS IN SCHIZOPHRENIA
por: Bani-Fatemi, Ali, et al.
Publicado: (2020)

S234. DEPRESSION AND SEXUAL FUNCTIONING: TWO NEGLECTED AND PREVALENT DOMAINS IN PEOPLE WITH SCHIZOPHRENIA
por: Lapa, Clara, et al.
Publicado: (2020)

S56. SWITCHING FROM RISPERIDONE TO PALIPERIDONE PALMITATE IN SCHIZOPHRENIA: CHANGES IN COGNITIVE FUNCTION
por: Tost Bonet, Meritxell, et al.
Publicado: (2020)

S126. THE RELATION OF THE PSYCHOSIS CONTINUUM WITH SCHIZOPHRENIA POLYGENIC RISK SCORE AND CANNABIS USE
por: Quattrone, Diego, et al.
Publicado: (2020)

S105. DIGITAL BIOMARKERS FOR THE ASSESSMENT OF COGNITIVE, BEHAVIORAL AND FUNCTIONAL OUTCOMES IN INDIVIDUALS WITH SCHIZOPHRENIA
por: Lindenmayer, Jean-Pierre, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_i6moup8m2u6ppq6omaftk66ep2